ReviewCurrent opinion in psychiatry2026
Pharmacological maintenance treatment in older age bipolar disorder.
Review in Current opinion in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe current review discusses the most recent developments in pharmacological maintenance treatment of older age bipolar disorder. RECENT
findingsOlder age bipolar disorder (OABD) applies to patients with bipolar disorder aged 50 years and over, a threshold reflecting the association between bipolar disorder and premature aging. Although medication effective in younger age bipolar disorder (YABD) are generally assumed to remain effective in older adults, the disease course becomes more complex in time and age-related changes in pharmacokinetics and pharmacodynamics require careful consideration. Despite the growing aging population, research targeting OABD remains limited. Therefore, the Global Aging and Geriatric Experiments in Bipolar Disorder (GAGE-BD) was initiated by the ISBD (International Society for Bipolar Disorder) OABD taskforce in 2016. Several recent studies on pharmacological maintenance therapy originated from this initiative and are discussed in this narrative review alongside other recent findings. However, no intervention studies have been published in the last 18 months, and the current evidence base largely consists of prospective cohort studies and cross-sectional data. SUMMARY: When looking at maintenance therapy in OABD, lithium remains first line of treatment but with an adjusted lower therapeutic range. Lithium therapy should not be withheld due to concerns of future kidney function decline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.